New drugs to tackle 'problematic' cholesterol

SPECIAL REPORT / New medicines soon expected to hit the European market will allow patients to lower their levels of bad cholesterol more substantially than is currently possible, opening new avenues for tackling heart diseases.

A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators in February, two months behind a rival product from Amgen.